Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
The negative symptoms of schizophrenia represent an impairment of normal emotional responses, thought processes and behaviors, and include blunting or flattening of affect, alogia/aprosody, avolition/apathy, anhedonia, and asociality. Negative symptoms contribute to a reduced quality of life, increased functional disability, increased burden of illness, and poorer long-term outcomes, to a greater degree than positive symptoms. Primary negative symptoms are prominent and persistent in up to 26% of patients with schizophrenia, and they are estimated to occur in up to 58% of outpatients at any given time. Negative symptoms respond less well to medications than positive symptoms, and to date treatment options for negative symptoms have been limited, with no accepted standard treatment. Modest benefits have been reported with a variety of different agents, including second-generation antipsychotics and add-on therapy with antidepressants and other pharmacological classes. Recent clinical research focusing on negative symptoms target novel biological systems, such as glutamatergic neurotransmission. Different approaches include: enhancing N-methyl-D-aspartate receptor function with agents that bind directly to the glycine ligand site or with glycine reuptake inhibitors; influencing the metabotropic glutamate receptor (mGluR2/3) with positive allosteric modulators; and stimulating nicotinic acetylcholine receptors. In conclusion, the lack of clearly efficacious pharmacological treatments for the management of negative symptoms represents a significant unmet need, especially considering the importance of these symptoms on patient outcomes. Hence, further research to identify and characterize novel pharmacological treatments for negative symptoms is greatly needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516
Negative Symptoms in Schizophrenia: Definition and Reliability
Andreasen, N. C. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290070020005 · Cited by 2,247
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
The NIMH-MATRICS Consensus Statement on Negative Symptoms
Kirkpatrick, B., Fenton, W. S., Carpenter, W. T., & Marder, S. R. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj053 · Cited by 1,311
The clinical assessment interview for negative symptoms (CAINS): Final development and validation
Kring, A. M., Gur, R. E., Blanchard, J. J., Horan, W. P., & Reise, S. P. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12010109 · Cited by 726
Negative Symptoms in Schizophrenia: Avolition and Occam's Razor
Foussias, G., & Remington, G. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn094 · Cited by 594 · cited 1×
“Several factor analyses of negative symptoms scales have shown two subdomains to be important: diminished expression and amotivation.(4,19) The first study to confirm the longitudinal stability of the dimension-based approach also showed it to be more predictive of psychosocial outcomes than older categorical definiti…”
BackgroundDysfunction of ventral striatal reward prediction in schizophrenia
Juckel, G., Schlagenhauf, F., Koslowski, M., Wüstenberg, T., Villringer, A., Knutson, B., Wrase, J., & Heinz, A. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2005.07.051 · Cited by 578
Berk, M., Copolov, D., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., Judd, F., Katz, F., Katz, P., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.03.004 · Cited by 552
Reward Processing in Schizophrenia: A Deficit in the Representation of Value
Gold, J. M., Waltz, J. A., Prentice, K. J., Morris, S. E., & Heerey, E. A. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn068 · Cited by 521
Buchanan, R. W., Javitt, D. C., Marder, S. R., Schooler, N. R., Gold, J. M., McMahon, R. P., Heresco-Levy, U., & Carpenter, W. T. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06081358 · Cited by 419
Cognitive Dysfunction in Schizophrenia: Convergence of γ-Aminobutyric Acid and Glutamate Alterations
Lewis, D. A., & Moghaddam, B. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1372 · Cited by 404
Levkovitz, Y., Mendlovich, S., Riwkes, S., Braw, Y., Levkovitch-Verbin, H., Gal, G., Fennig, S., Treves, I., & Kron, S. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04666yel · Cited by 387 · cited 1×
“Although minocycline did not improve overall psychopathology, two placebo-controlled studies showed a benefit in early-phase schizophrenia, especially on negative symptoms.(105,106) A systematic review and meta-analysis of selective serotonin-3 (5-HT 3 ) receptor antagonists, including ondansetron, granisetron, and tr…”
BackgroundBlanchard, J. J., Kring, A. M., Horan, W. P., & Gur, R. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq104 · Cited by 239
Negative symptoms of schizophrenia: a problem that will not go away
Stahl, S. M., & Buckley, P. F. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00947.x · Cited by 195
Marx, C. E., Keefe, R. S. E., Buchanan, R. W., Hamer, R. M., Kilts, J. D., Bradford, D. W., Strauss, J. L., Naylor, J. C., Payne, V. M., Lieberman, J. A., et al. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.26 · Cited by 193
Anhedonia and Emotional Experience in Schizophrenia: Neural and Behavioral Indicators
Dowd, E. C., & Barch, D. M. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.10.020 · Cited by 184
for the MEM-MD-29 Study Group, Lieberman, J. A., Papadakis, K., Csernansky, J., Litman, R., Volavka, J., Jia, X. D., & Gage, A. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.200 · Cited by 162
Hunter, R., & Barry, S. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2011.02.015 · Cited by 138
Cited by
Correll, C. U., & Schooler, N. R. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s225643 · Cited by 911
“59 Of note, however, the dopamine and glutamate hypotheses of schizophrenia are not mutually exclusive, with evidence in the literature supporting a role for both in the neurobiology of schizophrenia.”
Piper, J. D., & Piper, P. W. (2017) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12284 · Cited by 201
Treating Negative Symptoms in Schizophrenia: an Update
Remington, G., Foussias, G., Fervaha, G., Agid, O., Takeuchi, H., Lee, J., & Hahn, M. (2016) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-016-0075-8 · Cited by 167
“Reference has been made to these drugs in other reviews of negative symptoms [13, 18], and, like ECT, these drugs have a long history of augmentation use in schizophrenia as well as specific subpopulations (e.”
BackgroundWang, Y.-M., Zou, L.-Q., Xie, W.-L., Yang, Z.-Y., Zhu, X.-Z., Cheung, E. F. C., Sørensen, T. A., Møller, A., & Chan, R. C. K. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx194 · Cited by 44
Jørgensen, R., Licht, R. W., Lysaker, P. H., Munk-Jørgensen, P., Buck, K. D., Jensen, S. O. W., Hansson, L., & Zoffmann, V. (2015) · European Psychiatry · doi:10.1016/j.eurpsy.2014.12.007 · Cited by 35
“The finding regarding negative symptoms is worth noticing given how often this symptom component does not respond to treatment [7,31].”
Background
Metadata
- Authors
- Chue, P., & Lalonde, J.
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2014-05
- Volume
- 10
- Pages
- 777
- ISSN
- 1176-6328 (ISSN-L)
- OpenAlex
- W2099191115
- Cited by
- 76
- References
- 18
- FWCI
- 9.43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.